Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

the results of the first secondary endpoint, the statistical plan did not provide for a formal analysis of subsequent secondary endpoints(1).

Clinically meaningful differences were observed in time to SEGA progression. Of those patients receiving everolimus, 0% of patients (0 of 78) experienced disease progression (defined as increase in SEGA volume, worsening of non-target SEGAs, appearance of new lesions or new hydrocephalus), while 15% of patients (6 of 39) on placebo progressed(1).

Clinically meaningful differences were also observed in skin lesion response rate. A partial clinical response in skin lesions (corresponding to a 50% or greater improvement) was observed by Physician Global Assessment in 42% of patients (30 of 72) receiving everolimus, compared with 11% of patients (4 of 38) receiving placebo.  No complete responses were observed(1).

Additionally, a subset of patients (n=44) in this trial had angiomyolipomas, non-cancerous kidney tumors associated with TSC(1,6). As an exploratory endpoint, an angiomyolipoma response (corresponding to a volume reduction of 50% or greater) was observed in 53% of patients (16 of 30) receiving everolimus compared to 0% of patients (0 of 14) on placebo(1).

No adverse event (AE) leading to study drug discontinuation was observed during the study. The most common AEs in the everolimus versus the placebo arm (with an incidence of at least 20% in the everolimus arm) included mouth ulceration (32% vs. 5%), stomatitis (31% vs. 21%), convulsion (23% vs. 26%) and fever (22% vs. 15%). The most common Grade 3 AEs in the everolimus versus placebo arm (with an incidence of at least 5%) were stomatitis (8% vs. 3%), fever (6% vs. 0%) and convulsion (5% vs. 5%). One Grade 4 event of gastroenteritis was reported in the everolimus arm. Adverse events were mostly mild in severity (Grade 1/2) and were largely consistent with the known safety profile of everolimus. The most clinically notable AEs were infe
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... District of New Jersey has ... Sandoz, Inc. regarding United Therapeutics, Remodulin ® product.  In ... U.S. Patent No. 6,765,117 is both valid and enforceable ... generic product until the expiration of that patent in ...
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)...  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... to release its financial results for the fiscal 2014 ... market trading ends on Tuesday, September 9, 2014. ... 4:30 p.m. U.S. EDT on Tuesday, September 9, 2014 ... the Company,s financial results, commercial partnerships, and future outlook.  ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... March 24, 2011 When it comes to their ... to a January 2011 survey by the American Association ... losing their natural teeth. One way to help people ... During Root Canal Awareness Week, March 27 – April ...
... 2011 An educational symposium at the American Academy of ... learn more about the landscape of chronic opioid therapy. ... Opioid Therapy and Risk Management" and sponsored by Ameritox, will ... The event will be held Saturday, March 26 at 5:30 ...
Cached Medicine Technology:Dispelling Myths of Root Canals Through Education 2Symposium Highlights Evolving Landscape of Chronic Opioid Therapy 2
(Date:8/30/2014)... The SI Joint Evaluation and Treatment covers ... energy techniques. Michael P. Reiman PT, DPT, OCS, SCS, ... for the SI Joint. This PT online ... presentation with North American Seminars. , PT ... differential diagnosis approach to a thorough examination of the ...
(Date:8/30/2014)... What challenges exist in recruiting top talent ... concerns, and considerations? Sports Conflict Institute ’s ... with Woody Wommack, Southeast Football Recruiting Analyst of Rivals.com/Yahoo! ... recruiting. Notably, Wommack spoke on what the recruiting ... thinks are coming as a result of the O’Bannon ...
(Date:8/30/2014)... 30 August 2014: A new sudden death predictor ... for implantable cardioverter defibrillators (ICDs) in ESC Guidelines ... by Task Force Chairperson Professor Perry Elliott (UK). ... Management of Hypertrophic Cardiomyopathy" are published today on-line ... and on the ESC Website. Previous ESC Guidelines ...
(Date:8/29/2014)... Cancer is a life-changing illness that ... Eddie M. Leung knows the suffering that patients go through; ... cancer, a very rare and aggressive form of cancer. In ... by Xlibris), he shares a glimpse into his struggles as ... testimony that this disease can be overcome. , ...
(Date:8/29/2014)... Denver, Colorado (PRWEB) August 29, 2014 Daily Gossip ... the program was created by a former cold sores patient who ... this method is Ellie Gadsby, who decided to share her tips ... the world. , The author of the Get Rid of ... sores for 22 years, while in the least 4 years outbreaks ...
Breaking Medicine News(10 mins):Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3Health News:Sudden death predictor identifies ICD candidates in new ESC Guidelines 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 3Health News:Get Rid of Cold Sores Fast Review Reveals Simple Way to Eliminate Cold Sores in 12 Hours 2
... Hill-Rom Holdings, Inc. (NYSE: HRC ) today ... share. This dividend was declared by Hill-Rom,s Board of Directors ... 2009 to shareholders of record as of March 17, 2009. ... is a leading worldwide manufacturer and provider of medical technologies ...
... potential partners is easier to read than women,s, speed-dating study ... unattached this Valentine,s Day and you,re hoping to change that, ... easier to judge how interested a man is than it ... , Men who are attracted to women, it seems, are ...
... SYDNEY, Feb. 13 /PRNewswire-,FirstCall/ -- Thoratec Corporation ... leader in device-,based mechanical circulatory support therapies ... HeartWare International (ASX: HIN), which develops and,manufactures ... they,have entered into a definitive merger agreement ...
... through. , ... (Vocus) February 13, 2009 -- For centuries Mardi Gras - also known ... last bits of fat and meat in millions of homes in preparation for ... favorite foods. Meat is often chosen for this observance, as indicated by ...
... The Ensign Group, Inc. (Nasdaq: ... group of skilled nursing, rehabilitative care services and ... to issue its fourth quarter and fiscal year ... Wednesday, February 18, 2009.(Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ) ...
... also affect chances of having debilitating headaches , , THURSDAY, Feb. ... of migraine headaches in young and middle-aged adults, suggests a ... and the way body fat was distributed affected migraine risk. ... more likely to have migraines than those with smaller waistlines. ...
Cached Medicine News:Health News:Men, the Obvious Sex 2Health News:Men, the Obvious Sex 3Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 2Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 3Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 4Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 5Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 6Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 7Health News:Mardi Gras Gives Everyone a Big Fat Break Because Carnival Means "So Long" to Meat 2Health News:Mardi Gras Gives Everyone a Big Fat Break Because Carnival Means "So Long" to Meat 3Health News:The Ensign Group Schedules 2008 Year End Earnings Call for Thursday, February 19, 2009 2Health News:Belly Fat May Make Migraines More Likely 2
... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
... BrachySource iodine-125 implant is a combination of ... visibility that makes BrachySource I-125 implant an ... can be confident that every BrachySource I-125 ... management services which is required by clinicians ...
The silicone Tractfinder provides excellent fluoroscopic visualization. Manipulation of the movable core guidewire flexes the tapered proximal tip for maximum control in negotiating a tortuous ureter...
... Used for temporary internal drainage from the ... of a stricture. The segment with no ... lumen while preventing ingrowth of the ureteral ... peel-open packages. Intended for one-time use. CAUTION: ...
Medicine Products: